Royal Jelly

### Introduction to Royal Jelly Biochemistry

Royal jelly is a complex, milky-white secretion produced by the hypopharyngeal and mandibular glands of worker honeybees (*Apis mellifera*). Biologically, it serves as the exclusive food source for the queen bee throughout her life, triggering epigenetic changes that differentiate her from sterile worker bees. From a biochemical perspective, royal jelly is an intricate matrix composed of approximately 60-70% water, 9-18% proteins, 7-18% carbohydrates, 3-8% lipids, and trace amounts of vitamins, minerals, and polyphenols. The pharmacological interest in royal jelly stems primarily from its unique bioactive constituents, most notably the Major Royal Jelly Proteins (MRJPs) and the unusual medium-chain fatty acid 10-hydroxy-2-decenoic acid (10-HDA).

### Major Royal Jelly Proteins (MRJPs) and Royalactin

The protein fraction of royal jelly is dominated by a family of proteins known as Major Royal Jelly Proteins (MRJPs), which account for 80-90% of the total protein content. There are nine recognized members of this family (MRJP1 through MRJP9). MRJP1, often referred to as royalactin, is the most abundant and biologically significant. In the honeybee model, royalactin is the primary driver of queen differentiation. It achieves this by binding to the epidermal growth factor receptor (EGFR), initiating a signaling cascade that increases juvenile hormone levels, promotes ovarian development, and extends lifespan.

In mammalian models, the effects of MRJPs are less pronounced but still biologically relevant. MRJP1 has been shown to stimulate cellular proliferation and exhibit immunomodulatory properties. It can induce the secretion of tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) from macrophages, suggesting a role in immune system priming. Furthermore, MRJPs possess potent antioxidant capabilities. They can scavenge free radicals and upregulate endogenous antioxidant enzymes, such as superoxide dismutase (SOD) and glutathione peroxidase (GPx), through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. This antioxidant mechanism is a primary driver behind royal jelly's ability to improve oxidative stress biomarkers in clinical trials.

### Lipid Profile: The Role of 10-HDA

The lipid fraction of royal jelly is highly unusual compared to other natural products. It consists almost entirely of free fatty acids, with 10-hydroxy-2-decenoic acid (10-HDA) being the most prominent, comprising up to 50% of the total lipid content. 10-HDA is found exclusively in royal jelly and is often used as a marker of quality and authenticity for commercial supplements.

10-HDA exhibits a wide array of pharmacological activities. It is a potent anti-inflammatory agent, capable of inhibiting the production of pro-inflammatory cytokines by suppressing the nuclear factor-kappa B (NF-κB) signaling pathway. In vitro studies have demonstrated that 10-HDA can inhibit the expression of matrix metalloproteinases (MMPs), which are enzymes involved in tissue degradation and inflammation.

Moreover, 10-HDA plays a crucial role in royal jelly's cardiometabolic benefits. It has been shown to activate peroxisome proliferator-activated receptor alpha (PPAR-α), a nuclear receptor that regulates lipid metabolism. Activation of PPAR-α increases the expression of genes involved in fatty acid beta-oxidation and decreases the expression of genes involved in lipogenesis. This mechanism contributes to the reduction of serum triglycerides and low-density lipoprotein (LDL) cholesterol observed in human clinical trials. Additionally, 10-HDA may inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis, further contributing to its lipid-lowering effects.

### Phytoestrogenic Activity and Hormonal Modulation

One of the most clinically relevant aspects of royal jelly is its potential to modulate hormonal pathways, particularly in the context of menopause and premenstrual syndrome (PMS). Royal jelly contains several compounds that exhibit phytoestrogenic activity. These compounds possess a structural similarity to endogenous estrogens, allowing them to bind to estrogen receptors (ERs), specifically ER-beta (ERβ).

The affinity of royal jelly constituents for ERβ is relatively weak compared to endogenous estradiol, but it is sufficient to exert mild estrogenic effects in target tissues. This phytoestrogenic action is believed to be the primary mechanism behind royal jelly's ability to alleviate menopausal symptoms, such as vaginal dryness and hot flashes. By binding to ERβ in the vaginal epithelium, royal jelly may promote cellular proliferation and increase mucin production, thereby reducing dryness and discomfort.

In addition to its estrogenic effects, royal jelly has been investigated for its potential to influence testosterone production. Some studies have suggested that royal jelly supplementation can increase serum testosterone levels in healthy males. The proposed mechanism involves the stimulation of luteinizing hormone (LH) secretion from the pituitary gland, which in turn stimulates Leydig cells in the testes to produce testosterone. Furthermore, the antioxidant properties of royal jelly may protect Leydig cells from oxidative damage, preserving their steroidogenic capacity. However, it is important to note that the hormonal effects of royal jelly in humans are often described as inconsistent and difficult to predict, likely due to variations in the composition of the jelly and individual differences in metabolism.

### Pharmacokinetics and Bioavailability

The pharmacokinetics of royal jelly are complex and not fully elucidated, primarily because it is a multi-component mixture rather than a single active pharmaceutical ingredient. When ingested orally, the proteins (MRJPs) are subjected to enzymatic degradation in the gastrointestinal tract. However, some studies suggest that specific bioactive peptides derived from MRJPs may survive digestion and be absorbed intact into the systemic circulation, where they exert systemic effects.

The absorption of 10-HDA is better understood. As a medium-chain fatty acid, 10-HDA is readily absorbed across the intestinal epithelium via passive diffusion. Once in the bloodstream, it is transported to various tissues, including the liver, where it undergoes extensive metabolism via beta-oxidation. Interestingly, animal studies have shown that 10-HDA can cross the blood-brain barrier, which may explain some of the neuroprotective and cognitive-enhancing effects observed in preclinical models.

Despite its relatively good absorption, the half-life of 10-HDA is short, necessitating regular, daily dosing to maintain therapeutic levels. The bioavailability of royal jelly can also be influenced by the form of the supplement. Fresh royal jelly is highly unstable and must be kept frozen to prevent the degradation of its active constituents. Lyophilized (freeze-dried) royal jelly is more stable and has a longer shelf life, but the drying process must be carefully controlled to avoid the loss of volatile compounds and the denaturation of proteins.

### Impact on Glucose Metabolism and Insulin Sensitivity

While evidence is mixed, royal jelly has been investigated for its potential to improve glycemic control. The proposed mechanisms involve the modulation of insulin signaling pathways. Some bioactive peptides in royal jelly may enhance insulin receptor substrate-1 (IRS-1) phosphorylation, leading to increased translocation of glucose transporter type 4 (GLUT4) to the cell membrane and subsequent glucose uptake into skeletal muscle and adipose tissue. Additionally, the antioxidant properties of royal jelly may protect pancreatic beta cells from oxidative stress-induced apoptosis, preserving insulin secretory capacity. However, clinical trials have yielded conflicting results, with some showing small improvements in blood glucose levels and others showing no effect, particularly in diabetic populations.

### Conclusion on Mechanisms

In summary, royal jelly is a multifaceted biological substance with a diverse array of pharmacological activities. Its benefits for cardiometabolic health, oxidative stress, and menopausal symptoms are mediated by a complex interplay of its unique constituents, including MRJPs, 10-HDA, and phytoestrogens. While its mechanisms of action are increasingly well-understood in preclinical models, the translation of these findings to human clinical outcomes remains an area of active investigation, complicated by the inherent variability of this natural product.